Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Daiichi Sankyo Buy Of 20 Percent More Of India's Zenotech Suspended

This article was originally published in PharmAsia News

Executive Summary

Daiichi Sankyo has been ordered by an Indian court to postpone its attempt to buy shares in Zenotech Laboratories, an India-based maker of generic drugs. The court ordered the acquisition attempt suspended until the opposition of some shareholders can be resolved. Daiichi Sankyo has sought to buy 20 percent of Zenotech on its own. It already owns 47 percent through its earlier acquisition of Ranbaxy Laboratories. Minority stakeholders took the case to court challenging the Daiichi Sankyo offer as too low. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts